---
layout: default
title: Raloxifene
parent: Model Prediction Only (L5)
nav_order: 713
evidence_level: L5
indication_count: 4
---

# Raloxifene
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **4** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Raloxifene: From Unknown Original Indication to Duodenal Ulcer (Predicted, Low Confidence)

## One-Sentence Summary

> This evidence pack does not document Raloxifene's original approved indication (data gap), though supporting text identifies it as a selective estrogen receptor modulator (SERM).
> The TxGNN model predicts possible efficacy for **Duodenal Ulcer**,
> but **no clinical trials** and **no literature** currently support this direction — the evidence pack itself flags this as a likely false-positive prediction.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack (original_indications empty; MOA marked as data gap) |
| Predicted New Indication | Duodenal Ulcer (disease) |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Taiwan Market Status | Not marketed (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for Raloxifene is not available in this evidence pack (flagged as a Blocking/High-severity data gap). However, the model's own rationale text identifies Raloxifene as a **selective estrogen receptor modulator (SERM)** acting primarily on ERα/ERβ.

The rationale explicitly cautions that although gastrointestinal mucosa expresses low levels of estrogen receptors — and estrogenic signaling is theoretically associated with mucosal protection — **there is no experimental or clinical data supporting a therapeutic effect of Raloxifene on duodenal ulcer.** No mechanistic chain linking SERM activity to peptic ulcer healing has been established.

The evidence pack's own assessment states this high TxGNN score is "very likely a false positive arising from embedding similarity in the knowledge graph, without underlying biological relevance." The three other TxGNN candidates for this drug (hypoalphalipoproteinemia, duodenal obstruction, duodenogastric reflux) carry the same caveat — one is mechanistically contradictory (Raloxifene's lipid effects run opposite to the proposed indication), and two involve structural/mechanical or motility pathology with no plausible SERM mechanism. All four candidates are scored L5 (model-only) with a **Hold** recommendation at decision stage S0.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Taiwan Market Information

No registration records currently available — Raloxifene is not marketed in Taiwan under this dataset (market status: Not marketed / Not Marketed; 0 licenses on file).

---

## Safety Considerations

- **Drug Interactions**: 129 documented drug–drug interactions identified via DDInter. Severity levels for all listed interactions are recorded as "Unknown" in the source database, so clinical significance cannot be graded from this data alone. Representative interacting drugs include: Calcitriol, Pantoprazole, Glimepiride, Mesalazine, Doxycycline, Clotrimazole, Morphine, Metformin, Omeprazole, Lansoprazole, Sucralfate, Rosiglitazone, Vancomycin, Lactulose, Triamcinolone, Simvastatin, Nystatin, Nateglinide, Scopolamine, and Tetracycline (20 of 129 total shown).

Key warnings and contraindications are not available in this evidence pack — please refer to the package insert for this safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All four TxGNN-predicted indications for Raloxifene are model-only outputs (L5) with zero supporting clinical trials or literature. The drug's original indication and mechanism of action are undocumented data gaps, and the evidence pack's own mechanistic review flags the top candidate (duodenal ulcer) as a probable knowledge-graph false positive rather than a biologically grounded signal.

**To proceed, the following is needed:**
- TFDA package insert (warnings, contraindications) — currently a Blocking data gap
- Confirmed mechanism of action via DrugBank API query — currently a High-severity data gap
- Independent mechanistic or preclinical evidence connecting SERM activity to duodenal mucosal pathology before any further evaluation stage is considered
- Re-screening of TxGNN output for false-positive filtering given the pattern observed across all four ranked candidates for this drug
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

